Jason Dengyuemed

Jason Dengyuemed heeft een bestand toegevoegd Health
2026-01-19 07:51:20

Akeso’s Ivonescimab (PD-1/VEGF Bispecific Antibody) Submits BLA to the FDA
On January 12, 2026, Summit Therapeutics announced the submission of a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for ivonescimab, a PD-1/VEGF bispecific antibody developed by Akeso. The application seeks approval for ivonescimab in combination with chemotherapy as a second-line treatment for patients with locally advanced or metastatic non-squamous...

0 Reacties 0 aandelen 618 Views 0 voorbeeld

Please log in to like, share and comment!
Jason Dengyuemed heeft een bestand toegevoegd Health
2026-01-13 08:45:25

China's Innovative Medicines: Bringing New Hope to Global Patients
Imagine facing a diagnosis of advanced cancer or a chronic condition with limited options—then learning that breakthrough therapies from China are now reaching international markets, offering potentially more effective, accessible treatments. This is the reality unfolding in 2026, as Chinese biopharma accelerates from domestic innovation to global impact. The wave of innovative drug...

0 Reacties 0 aandelen 630 Views 0 voorbeeld

Please log in to like, share and comment!
Jason Dengyuemed heeft een bestand toegevoegd Health
2026-01-12 08:03:43

China's Innovative Drugs Going Global: A New Era for Worldwide Health in 2026
By HongKong DengYue Medicine The global pharmaceutical landscape is undergoing a profound transformation, and Chinese innovative drugs are at the forefront of this shift. In 2025, China's out-licensing (License-out) deals for innovative drugs reached a staggering total value of approximately $1,356.55 billion (around 9,483 billion RMB), with 157 transactions and upfront payments totaling $70...

0 Reacties 0 aandelen 653 Views 0 voorbeeld

Please log in to like, share and comment!
Jason Dengyuemed heeft een bestand toegevoegd Health
2026-01-09 07:33:27

Ivonescimab: Pioneering Progress in EGFR-Mutated Non-Squamous NSCLC Treatment
Edited by HongKong DengYue Medicine As we step into 2026, the landscape of cancer treatment continues to evolve, bringing rays of hope to patients worldwide who have long battled the uncertainties of lung cancer. Imagine being a patient diagnosed with EGFR-mutated non-squamous non-small cell lung cancer (NSCLC), having gone through the rigors of EGFR-TKI therapy only to face progression. The...

0 Reacties 0 aandelen 664 Views 0 voorbeeld

Please log in to like, share and comment!
Jason Dengyuemed heeft een bestand toegevoegd Health
2025-12-22 09:10:03

Explorando os Efeitos em Cascata da Operação Selada de Hainan nas Exportações Farmacêuticas da China
No panorama em constante evolução do comércio global, o setor farmacêutico da China está posicionado para transformações significativas, particularmente com recentes mudanças de política em regiões chave. Ao mergulharmos nas implicações da "operação selada" de Hainan – um movimento que...

0 Reacties 0 aandelen 1131 Views 0 voorbeeld

Please log in to like, share and comment!
Jason Dengyuemed heeft een bestand toegevoegd Health
2025-12-03 08:46:18

China's Innovative Drug Export: Accelerating a New Era of Globalization
In the rapidly evolving pharmaceutical landscape of 2025, Chinese innovative drug companies are not just participating but leading on the international stage with remarkable speed and ambition. This surge is driven by a combination of technological advancements, supportive government policies, and strategic global partnerships. Over the past 24 hours alone, several pivotal developments have...

0 Reacties 0 aandelen 1240 Views 0 voorbeeld

Please log in to like, share and comment!
Jason Dengyuemed heeft een bestand toegevoegd Health
2025-09-23 06:39:35

Ionis Launches Tryngolza™ (Olezarsen) for FCS With Positive Phase 3 Data and $595,000 Annual List Price
Ionis Pharmaceuticals, Inc. (NASDAQ: IONS) today announced the official U.S. launch of Tryngolza™ (olezarsen), a novel, once-monthly RNA-targeted therapy for familial chylomicronemia syndrome (FCS). The drug enters the market at an annual list price of $595,000, following its FDA approval in December 2024. First FDA-Approved Olezarsen Therapy for...

0 Reacties 0 aandelen 2759 Views 0 voorbeeld

Please log in to like, share and comment!
Jason Dengyuemed updated the profile picture
2025-09-23 06:21:05

0 Reacties 0 aandelen 983 Views 0 voorbeeld

Please log in to like, share and comment!

Meer blogs

Connect Freelancing Platform